MBIO Mustang Bio |
$1.53
+1.3% |
-19.5%
 |
MB-106
Relapsed or Refractory B-cell non-Hodgkin lymphomas (NHL) and Chronic Lymphocytic Leukemia (CLL)
|
Phase 1b/2
|
8/27/2025 - Clinical Trial
Moleculin Biotech, Inc., announced the completion of its Phase 1B/2 (MB-106) clinical trial evaluat…
Full Summary
|
ACST Acasti Pharma |
$3.11
|
|
GTX-104
IV infusion for patients experiencing Subarachnoid Hemorrhage (SAH)
|
NDA
|
8/27/2025 - FDA Accepted
Grace Therapeutics, Inc. announced that on August 22, 2025 the U.S. Food and Drug Administration (FD…
Full Summary
|
FBIO Fortress Biotech |
$2.34
-0.4% |
+18.2%
 |
MB-106
Relapsed or Refractory B-cell non-Hodgkin lymphomas (NHL) and Chronic Lymphocytic Leukemia (CLL)
|
Phase 1b/2
|
8/27/2025 - Clinical Trial
Moleculin Biotech, Inc., announced the completion of its Phase 1B/2 (MB-106) clinical trial evaluat…
Full Summary
|
ONC BeOne Medicines |
$300.14
-2.8% |
+1.9%
 |
Tislelizumab
Recurrent or Metastatic Nasopharyngeal Cancer
|
EC Approval
|
8/27/2025 - Approved
BeOne Medicines Ltd. announced that the European Commission (EC) has approved TEVIMBRA (tislelizum…
Full Summary
|
LLY Eli Lilly and Company |
$734.54
-0.2% |
-9.1%
 |
Verzenio (abemaciclib)
Hormone Receptor-Positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC)
|
Phase 3
|
8/27/2025 - Top-line results
Eli Lilly Announced Topline Results Phase 3 MonarchE Trial.
Full Summary
|
ABBV AbbVie |
$208.24
-0.1% |
+10.5%
 |
RINVOQ (upadacitinib)
Moderate to Severe Atopic Dermatitis
|
|
8/27/2025 - Provided Update
AbbVie today announced that Health Canada has issued a Notice of Compliance for RINVOQ® (upadacitini…
Full Summary
|
NRXP NRx Pharmaceuticals |
$2.58
-1.9% |
-11.9%
 |
NRX-100
To treat acute depression and suicidality
|
|
8/27/2025 - Provided Update
NRx Pharmaceuticals, announced its expanded access policy for NRX-100 (preservative-free ketamine) b…
Full Summary
|
TNGX Tango Therapeutics |
$6.90
+3.3% |
+3.4%
 |
Verzenio (abemaciclib)
Hormone Receptor-Positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC)
|
Phase 3
|
8/27/2025 - Top-line results
Eli Lilly Announced Topline Results Phase 3 MonarchE Trial.
Full Summary
|
BTAI BioXcel Therapeutics |
$3.96
-24.4% |
+132.9%
 |
IGALMI™
Sublingual film
|
Phase 3
|
8/27/2025 - Pivotal trial
BioXcel Therapeutics, announced that the SERENITY At-Home Pivotal Phase 3 trial evaluating the safet…
Full Summary
|
CLRB Cellectar Biosciences |
$4.82
+1.3% |
-4.2%
 |
Iopofosine I-131
Pediatric Brain and Solid Tumors
|
|
8/27/2025 - Abstract Presentation
Cellectar Biosciences, Inc. announced the acceptance of an abstract for oral presentation followed…
Full Summary
|
MRK Merck & Co., Inc. |
$84.16
-1.0% |
0.0%
 |
HER3-DXd
For the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC)
|
Phase 3
|
8/27/2025 - Dose Update
Merck announced that The first patient has been dosed in the HERTHENA-Breast04 phase 3 trial evalua…
Full Summary
|
ABCL AbCellera Biologics |
$4.35
-0.5% |
-11.6%
 |
ABCL575
For the treatment of moderate-to-severe atopic dermatitis (AD)
|
Phase 1
|
8/27/2025 - Dose Update
AbCellera announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, a …
Full Summary
|
AMLX Amylyx Pharmaceuticals |
$9.45
+3.2% |
+18.3%
 |
AMX0035
To treat amyotrophic lateral sclerosis (ALS)
|
|
8/27/2025 - Provided Update
Amylyx Pharmaceuticals, Inc. announced the decision to discontinue the ORION program of AMX0035 (so…
Full Summary
|
MBRX Moleculin Biotech |
$0.61
+11.3% |
+10.4%
 |
MB-106
Relapsed or Refractory B-cell non-Hodgkin lymphomas (NHL) and Chronic Lymphocytic Leukemia (CLL)
|
Phase 1b/2
|
8/27/2025 - Clinical Trial
Moleculin Biotech, Inc., announced the completion of its Phase 1B/2 (MB-106) clinical trial evaluat…
Full Summary
|
ALNY Alnylam Pharmaceuticals |
$454.18
+0.7% |
+39.8%
 |
Cemdisiran
Immunoglobulin A Nephropathy (IgAN)
|
Phase 3
|
8/26/2025 - Endpoint Met
Regeneron Pharmaceuticals, announced that the primary and key secondary endpoints were met in the P…
Full Summary
|
IXHL Incannex Healthcare |
$0.67
-5.6% |
-43.7%
 |
PSX-001
In Patients with Generalised Anxiety Disorder to Proceed
|
Phase 2
|
8/26/2025 - Positive Data
Incannex Healthcare Inc is pleased to report positive data from its Phase 2 clinical trial of PSX-0…
Full Summary
|
LLY Eli Lilly and Company |
$734.54
-0.2% |
-9.1%
|
orforglipron
Orforglipron for the treatment of obesity and overweight
|
Phase 3
|
8/26/2025 - Top-line results
Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluatin…
Full Summary
|
GILD Gilead Sciences |
$113.92
-0.7% |
+0.8%
 |
Lenacapavir
For the treatment of HIV infection
|
European Commission Marketing Authorization
|
8/26/2025 - Marketing authorization
Gilead Sciences, Inc announced that the European Commission (EC) has granted marketing authorizatio…
Full Summary
|
BTAI BioXcel Therapeutics |
$3.96
-24.4% |
+132.9%
|
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
|
|
8/26/2025 - Provided Update
BioXcel Therapeutics, announced that it will host an investor call and live webcast at 8 a.m. ET, Au…
Full Summary
|
LPCN Lipocine |
$3.01
-2.9% |
-9.6%
 |
LPCN 2101
Epilepsy
|
|
8/26/2025 - Abstract
Lipocine Inc announced that two abstracts related to LPCN 2101 have been accepted for poster presen…
Full Summary
|
MRKR Marker Therapeutics |
$0.94
-6.0% |
-39.4%
 |
MT-601
Pancreatic cancer
|
|
8/26/2025 - Primary Endpoint
Marker Therapeutics, Inc. today provided an update on the progress and clinical observations from …
Full Summary
|
GMAB Genmab A/S |
$24.78
+1.0% |
+7.3%
 |
Rina-S
In Heavily Pretreated Patients with Ovarian and Endometrial Cancers
|
Breakthrough Therapy
|
8/26/2025 - Designation Grant
Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough…
Full Summary
|
REGN Regeneron Pharmaceuticals |
$586.96
-0.1% |
+5.1%
 |
Cemdisiran
Immunoglobulin A Nephropathy (IgAN)
|
Phase 3
|
8/26/2025 - Endpoint Met
Regeneron Pharmaceuticals, announced that the primary and key secondary endpoints were met in the P…
Full Summary
|
ALLR Allarity Therapeutics |
$1.59
+11.2% |
+42.0%
 |
Stenoparib
For ovarian cancer (AOC)
|
Fast Track
|
8/26/2025 - Designation Grant
Allarity Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has granted F…
Full Summary
|
MNOV MediciNova |
$1.34
-1.5% |
-7.6%
 |
MN-166 (ibudilast)
Inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines
|
Phase 2b/3
|
8/26/2025 - Enrollment Update
MediciNova announces that it successfully achieved enrollment of the target number of participants …
Full Summary
|
MRK Merck & Co., Inc. |
$84.16
-1.0% |
0.0%
|
VERQUVO (vericiguat)
Chronic Heart Failure and Reduced Ejection Fraction
|
|
8/25/2025 - Clinical Trial
Merck announced that new clinical trial and outcomes research data will be presented at the European…
Full Summary
|
CYTK Cytokinetics |
$37.83
-0.9% |
+3.3%
 |
Aficamten
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
|
|
8/25/2025 - Presentation
Cytokinetics announced five presentations related to aficamten at the European Society of Cardiology…
Full Summary
|
TBPH Theravance Biopharma |
$13.80
|
+24.8%
 |
Ampreloxetine
Symptomatic neurogenic orthostatic hypotension
|
Phase 3
|
8/25/2025 - Enrollment Completion
Theravance Biopharma, Inc. announced completion of enrollment in the open-label portion of its pivot…
Full Summary
|
BIIB Biogen |
$136.36
-0.3% |
+5.5%
 |
Lecanemab (BAN2401)
Anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD)
|
|
8/25/2025 - Provided Update
Eisai Co., and Biogen Inc. announced today that the anti-amyloid beta (Aβ) monoclonal antibody "LEQE…
Full Summary
|
PTGX Protagonist Therapeutics |
$61.43
+7.8% |
+9.2%
 |
Rusfertide (PTG-300)
Polycythemia vera (PV)
|
Breakthrough Therapy
|
8/25/2025 - Designation Grant
Protagonist Therapeutic announced today that rusfertide, a potential first-in-class hepcidin-mimetic…
Full Summary
|
PDSB PDS Biotechnology |
$1.28
-0.8% |
+8.5%
 |
VERSATILE-002
Treatment of recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer.
|
Phase 2
|
8/25/2025 - Survival data
PDS Biotechnology announced final topline survival data from its VERSATILE-002 Phase 2 clinical tri…
Full Summary
|
SBBP Strongbridge Biopharma |
$2.00
|
|
RECORLEV (levoketoconazole)
endogenous Cushing's syndrome
|
|
8/25/2025 - Provided Update
Xeris Biopharma Holdings, Inc announced the U.S Patent and Trademark Office has issued patent numbe…
Full Summary
|
AMRN Amarin |
$15.47
-0.5% |
+3.2%
 |
VASCEPA/VAZKEPA (icosapent ethyl)
Prior Peripheral Artery Disease (PAD)
|
|
8/25/2025 - Presentation
Amarin Corporation plc announced upcoming presentations at the European Society of Cardiology (ESC) …
Full Summary
|
EOLS Evolus |
$7.58
-0.9% |
-18.3%
 |
Evolysse™
Evolus dermal filler,
|
|
8/25/2025 - Top-line results
Evolus, Inc announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an inj…
Full Summary
|
ARGX argenex |
$707.96
0.0% |
+18.9%
 |
VYVGART (efgartigimod alfa)
For Adults with Primary Immune Thrombocytopenia
|
|
8/25/2025 - Top-line data
argenx SE announced positive topline data from the pivotal ADAPT SERON study of VYVGART® (IV: efgart…
Full Summary
|
BBIO BridgeBio Pharma |
$49.59
+1.5% |
+7.3%
 |
Acoramidis (ATTRibute-CM)
Symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM)
|
|
8/25/2025 - Oral presentation
BridgeBio Pharma, Inc. announced today that one rapid-fire oral presentation on additional open-lab…
Full Summary
|
AMGN Amgen |
$287.97
-0.6% |
-4.4%
 |
Repatha (Evolocumab)
HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular (CV) events
|
|
8/25/2025 - FDA Approval
Amgen announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of R…
Full Summary
|
CSTL Castle Biosciences |
$22.28
+4.4% |
+36.4%
 |
DecisionDx-SCC
High-risk cutaneous squamous cell carcinoma (SCC)
|
|
8/25/2025 - Publication
Castle Biosciences, announced the publication of two new studies related to its DecisionDx-SCC test…
Full Summary
|
BMY Bristol Myers Squibb |
$47.60
+0.8% |
+0.2%
 |
CAMZYOS® (mavacamten)
For the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy
|
|
8/25/2025 - Presentation
Bristol Myers Squibb announced the presentation of new clinical and real-world data from its cardiov…
Full Summary
|
CPRX Catalyst Pharmaceuticals |
$20.19
+1.3% |
-2.9%
 |
FIRDAPSE®
For the treatment of LEMS
|
|
8/25/2025 - Provided Update
Catalyst Pharmaceuticals, Inc. announced that the Company and its licensor SERB S.A. ("SERB") have …
Full Summary
|
XERS Xeris Biopharma |
$7.99
+0.5% |
+57.6%
 |
RECORLEV (levoketoconazole)
endogenous Cushing's syndrome
|
|
8/25/2025 - Provided Update
Xeris Biopharma Holdings, Inc announced the U.S Patent and Trademark Office has issued patent numbe…
Full Summary
|
NTRA Natera |
$163.04
-1.6% |
+18.1%
 |
Signatera
MRD Test for cancer therapies
|
|
8/25/2025 - New Data
Natera, Inc announced that it will present new data at the 2025 International Association for the S…
Full Summary
|
BFRA Biofrontera |
$2.60
|
|
Ameluz
For treatment of actinic keratosis
|
Phase 2b
|
8/25/2025 - evaluation
Biofrontera Inc. announced that the final patient in its Phase 2b clinical trial evaluating Ameluz® …
Full Summary
|
SION Sionna Therapeutics |
$25.13
-0.4% |
+26.6%
 |
SION-451
cystic fibrosis transmembrane conductance regulator (CFTR) protein
|
Phase 1
|
8/25/2025 - Dose Update
Sionna Therapeutics, announced that the first subjects have been dosed in a Phase 1 trial evaluatin…
Full Summary
|
ALKS Alkermes |
$29.25
+0.9% |
+11.9%
 |
ALKS 2680
For the treatment of narcolepsy
|
|
8/25/2025 - presented results
Alkermes plc announced plans to present detailed results from its Vibrance-1 phase 2 study evaluatin…
Full Summary
|
CTXR Citius Pharmaceuticals |
$1.37
+3.8% |
-11.0%
 |
LYMPHIR
For the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
|
8/22/2025 - Provided Update
Citius Oncology, Inc the oncology-focused subsidiary of Citius Pharmaceuticals, Inc announced that …
Full Summary
|
MRNA Moderna |
$25.10
+1.5% |
-26.0%
 |
SPIKEVAX (COVID-19 Vaccine, mRNA)
COVID-19 in individuals 18 years of age and older
|
Health Canada
|
8/22/2025 - Authorization
Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikev…
Full Summary
|
PRTC PureTech Health |
$18.01
-8.3% |
-5.6%
 |
LYT-100
Idiopathic Pulmonary Fibrosis
|
|
8/21/2025 - Provided Update
PureTech Health plc demonstrated its growing leadership in idiopathic pulmonary fibrosis (IPF) at t…
Full Summary
|
SEPN Septerna |
$12.63
-0.6% |
-8.7%
 |
SEP-631
For Mast Cell Diseases
|
Phase 1
|
8/21/2025 - Dosing Update
Septerna, announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a…
Full Summary
|
ABBV AbbVie |
$208.24
-0.1% |
+10.5%
|
RINVOQ (upadacitinib)
Moderate to Severe Atopic Dermatitis
|
|
8/21/2025 - Top-line results
AbbVie announced positive topline results from the second of two pivotal studies of the Phase 3 UP-A…
Full Summary
|
DVAX Dynavax Technologies |
$10.26
-1.7% |
-9.1%
 |
Z-1018
Shingles Vaccine Profile
|
Phase 1/2
|
8/21/2025 - Top-line results
Dynavax Technologies announced positive topline results from Part 1 of its randomized, observer-bli…
Full Summary
|
CRNX Crinetics Pharmaceuticals |
$30.40
-1.7% |
+0.3%
 |
Atumelnant
In Congenital Adrenal Hyperplasia (CAH)
|
Orphan Drug
|
8/21/2025 - Designation Grant
Crinetics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted …
Full Summary
|
REGN Regeneron Pharmaceuticals |
$586.96
-0.1% |
+5.1%
|
EYLEA (aflibercept)
Wet age-related macular degeneration (wet AMD)
|
EC Approval
|
8/21/2025 - Approved
Alvotech announced that the European Commission has approved Mynzepli® as a biosimilar to Eylea® (af…
Full Summary
|
STTK Shattuck Labs |
$1.00
-2.0% |
+21.8%
 |
SL-325
In inflammatory bowel disease
|
Phase 1
Target date: Q3 2025
|
8/21/2025 - Dose Update
Shattuck Labs, Inc announced that The Company is on track to dose the first participant in its Phas…
Full Summary
|
STTK Shattuck Labs |
$1.00
-2.0% |
+21.8%
|
SL-325
In inflammatory bowel disease
|
IND
|
8/21/2025 - Provided Update
Shattuck Labs, Inc announced that the Company's Investigational New Drug (IND) application submitte…
Full Summary
|
CTSO Cytosorbents |
$0.93
|
-1.3%
 |
DrugSorb-ATR
Antithrombotic Removal System
|
|
8/20/2025 - Regulatory Update
CytoSorbents Corporation updates the regulatory status of its appeal with the U.S. Food and Drug Ad…
Full Summary
|
PFE Pfizer |
$25.08
+0.6% |
+3.1%
 |
PAXLOVID
Covid-19
|
|
8/20/2025 - Provided Update
Enanta Pharmaceuticals, Inc announced today that it has filed suit in the Unified Patent Court (UP…
Full Summary
|
NVCR NovoCure |
$11.91
+0.7% |
+2.3%
 |
Tumor Treating Fields - PANOVA-3
Locally advanced pancreatic cancer
|
|
8/20/2025 - Application Submitted
Novocure announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Adm…
Full Summary
|
BMY Bristol Myers Squibb |
$47.60
+0.8% |
+0.2%
|
Opdivo (nivolumab)
Resected esophageal or gastroesophageal junction (GEJ) cancer in the adjuvant setting
|
|
8/20/2025 - FDA Approval
Agilent Technologies Inc. announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA app…
Full Summary
|
SVRA Savara |
$3.29
-0.6% |
+23.7%
 |
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
Phase 2
|
8/20/2025 - Results
Savara Inc. announced that the results from the Phase 3 IMPALA-2 clinical trial will be published on…
Full Summary
|
EOLS Evolus |
$7.58
-0.9% |
-18.3%
|
Evolysse™
Evolus dermal filler,
|
|
8/20/2025 - Application Submitted
Evolus, Inc. announced that it has submitted the final module of its Premarket Approval (PMA) applic…
Full Summary
|
RCKT Rocket Pharmaceuticals |
$3.32
-2.1% |
+6.8%
 |
RP-A501
Danon Disease
|
|
8/20/2025 - Lifted Clinical Hold
Rocket Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted t…
Full Summary
|
RYTM Rhythm Pharmaceuticals |
$102.30
+1.1% |
+19.4%
 |
Setmelanotide (HO)
Hypothalamic Obesity
|
supplemental New Drug Application (sNDA)
|
8/20/2025 - FDA Accepted
Rhythm Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has accepted…
Full Summary
|
MIRA MIRA Pharmaceuticals |
$1.37
-1.4% |
-20.3%
 |
Ketamir-2
To treat depression and treatment-resistant depression (TRD).
|
Phase 1
|
8/19/2025 - Dose Update
MIRA Pharmaceuticals, Inc. announced the successful completion of the Single Ascending Dose (SAD) p…
Full Summary
|
BTAI BioXcel Therapeutics |
$3.96
-24.4% |
+132.9%
|
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
|
Phase 3
|
8/19/2025 - Provided Update
BioXcel Therapeutics announced completion of the database lock for its SERENITY At-Home pivotal Pha…
Full Summary
|
VKTX Viking Therapeutics |
$26.62
+2.2% |
-19.8%
 |
VK2735
Metabolic disorders
|
Phase 2
|
8/19/2025 - Top-line results
Viking Therapeutics, Inc. announced positive top-line results from the company's Phase 2 clinical t…
Full Summary
|
ALXO ALX Oncology |
$1.20
+9.1% |
+91.7%
 |
ALX2004
For the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors
|
|
8/19/2025 - Dose Update
ALX Oncology Holdings Inc announced that the first patient has been dosed in the Company's Phase 1 …
Full Summary
|
ALT Altimmune |
$3.67
+6.7% |
-8.9%
 |
pemvidutide
for the treatment of obesity and MASH
|
Fast Track
|
8/19/2025 - Decision Deferred
Altimmune, Inc announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track des…
Full Summary
|
ALRN Aileron Therapeutics |
|
|
LTI-03
In Idiopathic Pulmonary Fibrosis
|
Phase 2
|
8/19/2025 - Clinical Trial
Rein Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) h…
Full Summary
|
ALDX Aldeyra Therapeutics |
$5.85
-0.7% |
+10.0%
 |
ADX-2191
Primary vitreoretinal lymphoma (PVRL)
|
Fast Track
|
8/19/2025 - Designation Grant
Aldeyra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted f…
Full Summary
|
DCTH Delcath Systems |
$10.94
-1.6% |
-4.1%
 |
HEPZATO KIT
For the treatment of metastatic uveal melanoma (mUM).
|
Phase 2
|
8/19/2025 - Dose Update
Delcath Systems, Inc. announced that the first patient has been dosed at the City of Hope National …
Full Summary
|
MREO Mereo BioPharma Group |
$1.76
|
|
Vantictumab
for Autosomal Dominant Osteopetrosis Type 2
|
|
8/19/2025 - Provided Update
āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for th…
Full Summary
|
MDGL Madrigal Pharmaceuticals |
$425.06
+0.0% |
+44.5%
 |
Rezdiffra (resmetirom)
for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
|
European Commission Conditional Marketing Authorization
|
8/19/2025 - Marketing authorization
Madrigal Pharmaceuticals, Inc announced that the European Commission (EC) has granted conditional m…
Full Summary
|
HCM HUTCHMED |
$14.96
-4.3% |
-16.8%
 |
SANOVO
for Certain Lung Cancer Patients
|
Phase 3
|
8/19/2025 - Enrollment Completion
HUTCHMED (China) Limited announces the completion of patient enrollment of SANOVO, a China Phase II…
Full Summary
|
CLDX Celldex Therapeutics |
$22.60
+3.9% |
+2.7%
 |
Barzolvolimab
For Prurigo Nodularis
|
Phase 2
|
8/19/2025 - Top-line results
Celldex Therapeutics, Inc today reported topline results from the Company's ongoing Phase 2 study o…
Full Summary
|
NMTC NeuroOne Medical Technologies |
$0.75
-2.7% |
-12.0%
 |
OneRF
Ablation System for creation of radiofrequency ("RF") lesions in nervous tissue for functional neurosurgical procedures.
|
|
8/18/2025 - FDA Clearance
NeuroOne Medical Technologies Corporation announced that it has received U.S. Food and Drug Adminis…
Full Summary
|
SNGX Soligenix |
$3.00
-4.5% |
+134.4%
 |
SGX945
In the Treatment of Aphthous Ulcers in Behçet's Disease
|
Orphan Drug
|
8/18/2025 - Designation Grant
Soligenix, Inc. announced that the Office of Orphan Products Development of the United States (U.S.…
Full Summary
|
NTRA Natera |
$163.04
-1.6% |
+18.1%
|
IMvigor011
in Muscle-Invasive Bladder Cancer
|
Phase 3
|
8/18/2025 - Positive Results
Natera, Inc. announced positive topline results from the randomized, phase III IMvigor011 clinical t…
Full Summary
|
RGNX REGENXBIO |
$8.82
-3.3% |
+0.3%
 |
RGX-121
MPS II (Hunter Syndrome)
|
BLA
|
8/18/2025 - Provided Update
REGENXBIO Inc. announced that the U.S. Food and Drug Administration (FDA) extended its review timeli…
Full Summary
|
ENLV Enlivex Therapeutics |
$1.09
+0.9% |
-13.5%
 |
Allocetra
Sepsis
|
|
8/18/2025 - Top-line results
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial…
Full Summary
|
BTAI BioXcel Therapeutics |
$3.96
-24.4% |
+132.9%
|
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
|
supplemental New Drug Application (sNDA)
Target date: Q1 2026
|
8/18/2025 - sNDA Filing
BioXcel Therapeutics, announced that sNDA submission on track for Q1 2026
Full Summary
|
CAPR Capricor Therapeutics |
$6.25
-3.4% |
-8.0%
 |
StealthX
exosome-based vaccine.
|
Phase 1
|
8/18/2025 - Dose Update
Capricor Therapeutics announced that the first subjects have been dosed in a Phase 1 clinical trial…
Full Summary
|
BMY Bristol Myers Squibb |
$47.60
+0.8% |
+0.2%
|
iza-bren
For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
|
Breakthrough Therapy
|
8/18/2025 - Designation Grant
SystImmune Inc. and Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA)…
Full Summary
|
MRK Merck & Co., Inc. |
$84.16
-1.0% |
0.0%
|
I-DXd
In patients with pretreated extensive-stage small cell lung cancer (ES-SCLC).
|
Breakthrough Therapy
|
8/18/2025 - Designation Grant
Daiichi Sankyo and Merck announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough…
Full Summary
|
LH Labcorp |
$279.55
+0.4% |
+7.0%
 |
Lumipulse®
Blood Test for Alzheimer's Disease
|
|
8/18/2025 - Provided Update
Labcorp announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first…
Full Summary
|
IRD Opus Genetics |
$1.20
-0.4% |
|
OPGx-BEST1
For the treatment of bestrophin-1 (BEST1)-related IRD.
|
IND
|
8/18/2025 - FDA Accepted
Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigat…
Full Summary
|
RDY Dr. Reddy's Laboratories |
$14.24
+0.2% |
-3.2%
 |
Carac
For the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
|
|
8/18/2025 - Launch
Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's …
Full Summary
|
SVRA Savara |
$3.29
-0.6% |
+23.7%
|
Molgramostim (IMPALA-2)
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
8/18/2025 - FDA Accepted
Savara Inc announced the acceptance of three abstracts for poster presentation at the European Resp…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$30.08
+1.8% |
+8.9%
 |
DTX401 AAV
For the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
|
BLA
|
8/18/2025 - rolling submission
Ultragenyx Pharmaceutical announced the initiation of a rolling submission of a Biologics License A…
Full Summary
|
PSTV Plus Therapeutics |
$0.49
-3.0% |
-15.5%
 |
REYOBIQ™
For Patients with Leptomeningeal Metastases
|
Phase 1
|
8/18/2025 - Positive Data
Plus Therapeutics, Inc. announces positive data from the ReSPECT-LM Phase 1 single dose escalation …
Full Summary
|
PFE Pfizer |
$25.08
+0.6% |
+3.1%
|
PAXLOVID
Covid-19
|
Phase 2
|
8/18/2025 - evaluation
Traws Pharma, Inc. announced receipt from the Human Research Ethics Committee (HREC) of approval to…
Full Summary
|
BTAI BioXcel Therapeutics |
$3.96
-24.4% |
+132.9%
|
BXCL501 (SERENITY)
Schizophrenia and bipolar disorders
|
supplemental New Drug Application (sNDA)
|
8/18/2025 - Positive Opinion
BioXcel Therapeutics, announced that it has received positive pre-sNDA meeting responses from the U…
Full Summary
|
RARE Ultragenyx Pharmaceutical |
$30.08
+1.8% |
+8.9%
|
DTX401 AAV
For the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
|
BLA
Target date: Q4 2025
|
8/18/2025 - BLA Filing
Ultragenyx Pharmaceutical announced that company has submitted the non-clinical and clinical modules…
Full Summary
|
IOVA Iovance Biotherapeutics |
$2.42
-1.2% |
-18.0%
 |
Lifileucel
For the Treatment of Advanced Melanoma
|
|
8/18/2025 - Notice of Compliance
Iovance Biotherapeutics, announced Health Canada has issued a Notice of Compliance with Conditions …
Full Summary
|
MMSI Merit Medical Systems |
$90.79
+1.9% |
+7.5%
 |
WRAPSODY
Cell-Impermeable Endoprosthesis (CIE).
|
|
8/18/2025 - Enrollment Update
Merit Medical Systems announced today the successful enrollment of the first patient in the WRAP Nor…
Full Summary
|
VNDA Vanda Pharmaceuticals |
$4.62
-1.1% |
-1.7%
 |
HETLIOZ
For treat jet lag disorder
|
|
8/18/2025 - Regulatory Update
Vanda Pharmaceuticals Inc. announced that it secured a landmark victory over the U.S. Food and Drug…
Full Summary
|
AAPG Ascentage Pharma Group International |
$41.40
-3.1% |
+5.4%
 |
lisaftoclax
In Venetoclax-Refractory Patients
|
|
8/17/2025 - FDA Clearance
Ascentage Pharma announced that it has received clearance by the U.S. Food and Drug Administration …
Full Summary
|
VERU Veru |
$3.29
-5.2% |
-37.3%
 |
Wegovy
For cardiovascular risk reduction in adults with known heart disease and overweight or obesity
|
|
8/15/2025 - FDA approved
Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved a new indication …
Full Summary
|
GBT Global Blood Therapeutics |
$68.49
|
|
Inclacumab + GBT601
Sickle Cell Disease
|
Phase 3
|
8/15/2025 - Results
Pfizer Inc announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigati…
Full Summary
|
BIOA BioAge Labs |
$4.74
+2.8% |
+4.6%
 |
BGE-102
For the treatment of obesity.
|
Phase 1
|
8/15/2025 - Dose Update
BioAge Labs, Inc. announced that the first participant has been dosed in a Phase 1 clinical trial ev…
Full Summary
|
MarketBeat All Access